Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-01-04

Clinical Trial Update: Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity [Phase 1]

View source ↗

Summary

Phase 1 trial comparing subcutaneous vs intramuscular administration of DENVax (TDV) focusing on safety and immunogenicity in dengue fever.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DENVax (TDV) (tetravalent dengue vaccine)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 1 | Status: COMPLETED | Results posted: 2017-01-04